ESPR Q3 2020 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$519M

Q3 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4M+290.7% YoY

Gross Profit

$4M92.8% margin

Operating Income

-$81M-2101.5% margin

Net Income

-$85M-2229.0% margin

EPS (Diluted)

$-3.07

QoQ Revenue Growth

-98.2%

Cash Flow

Operating Cash Flow

-$87M

Free Cash Flow

-$87M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$251M

Total Liabilities

$242M

Stockholders' Equity

$9M

Cash & Equivalents

$216M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$981,000	+290.7%
Gross Profit	$4M	-$47M	+107.5%
Operating Income	-$81M	-$66M	-22.5%
Net Income	-$85M	-$68M	-24.9%

Revenue Segments

Collaboration Revenue

$502,00050%

Product Sales Bulk Tablets Nilemdo And Nustendi

$500,00050%